EN | UA
EN | UA

Help Support

Back

HOPE-3 trial found continuous beneficial effect of Rosuvastatin for about 3 years even after its discontinuation

HOPE-3 trial found continuous beneficial effect of Rosuvastatin for about 3 years even after its discontinuation HOPE-3 trial found continuous beneficial effect of Rosuvastatin for about 3 years even after its discontinuation
HOPE-3 trial found continuous beneficial effect of Rosuvastatin for about 3 years even after its discontinuation HOPE-3 trial found continuous beneficial effect of Rosuvastatin for about 3 years even after its discontinuation

What's new?

Rosuvastatin has long-lasting advantages in people without cardiovascular (CV) diseases but are at risk of CV events..

Use of Rosuvastatin 10 mg was found to provide CV benefits and lowers blood pressure (BP) in those with elevated systolic BP for at least 3 years even after its stoppage in people without CV disease representing a legacy effect, outcomes of 8.7 years of an extended follow-up study of Heart Outcomes Evaluation Prevention (HOPE)-3 trial portrayed.

In order to study if the CV events lowering benefits of Rosuvastatin 10 mg daily is sustained or improved or attenuated even after its cessation,  the patients with elevated systolic BP were called to participate in this 8.7 years ( 5.6 years plus 3.1 more years of observation). The first co-primary outcome comprised of MACE-1 i.e. myocardial infarction, stroke, or CV death. The second co-primary outcome comprised of MACE-2 i.e. MACE-1 along with resuscitated cardiac arrest, heart failure, or coronary revascularization.

Out of 11,994 surviving individuals of the HOPE-3 study, 9326 (78%) participated in this study. Compared with placebo, the individuals initially randomized to rosuvastatin had a 20% and 17% additional reduction in MACE-1 and MACE-2, respectively during a follow-up of 8.7 years. During the active or after the trial observation period, no BP lowering benefit was perceived, but MACE-1 was reduced by 24% in individuals with high systolic BP over the total follow-up period.

Source:

European Heart Journal

Article:

Lowering cholesterol, blood pressure, or both to prevent cardiovascular events: results of 8.7 years of follow-up of Heart Outcomes Evaluation Prevention (HOPE)-3 study participants

Authors:

Jackie Bosch et al.

Comments (3)

You want to delete this comment? Please mention comment Invalid Text Content Text Content cannot me more than 1000 Something Went Wrong Cancel Confirm Confirm Delete Hide Replies View Replies View Replies en ua ru
Try: